Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy
Cancer Communications · 2025-11 · 45 (11) · 1513-1546
DOI: 10.1002/cac2.70067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 12.10.2025. Verfasst von Yuheng Yan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China. Hauptthemen laut MEDLINE: Nucleotidyltransferases, Neoplasms, Membrane Proteins, Immunotherapy. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 337 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Natural Science Foundation of China, Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital.
Abstract (Originalsprache)
Since its discovery, the cyclic GMP‐AMP synthase (cGAS)‐stimulator of the interferon gene (STING) signaling pathway has been considered a pivotal component of innate immunity and a promising target for cancer immunotherapy. Beyond its canonical role in pathogen defense, accumulating evidence has demonstrated that the cGAS‐STING pathway critically regulates diverse cellular processes, including cellular senescence, autophagy, cell death, and tumor immunosurveillance; therefore, dysregulation of this pathway correlates with the pathogenesis and progression of various human diseases, ranging from autoimmune and inflammatory disorders to cancer. Herein, we reviewed the regulatory mechanisms and cellular functions of the cGAS‐STING pathway, highlighting its essential role in maintaining immune homeostasis. We systematically discussed the dual roles of the cGAS‐STING pathway in cancer immunity, in which it triggers both antitumor and immunosuppressive effects. Finally, we summarized the recent advances and challenges in therapeutic strategies targeting the cGAS‐STING pathway and discussed the next generation of therapies, including nanomaterials, antibody‐drug conjugates, engineered bacteria, alternative strategies, optogenetic approaches, and combination strategies. We hope that our efforts will advance the understanding of the fundamental principles of innate immune recognition and response, and provide novel directions for improving the clinical outcomes of cGAS‐STING‐targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.
- Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, P. R. China.
- Department of Breast Surgery, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, Zhejiang, P. R. China.
ORCID-Profile: Yuheng Yan
Förderung
- the National Natural Science Foundation of China
- Research and Innovation Team Project for Scientific Breakthroughs at Shanxi Bethune Hospital
Zitieren
APA
Yan, Y., Tan, X., Song, B., Yi, M., Chu, Q., & Wu, K. (2025). Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy. Cancer Communications, 45(11), 1513-1546. https://doi.org/10.1002/cac2.70067
Vancouver
Yan Y, Tan X, Song B, Yi M, Chu Q, Wu K. Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy. Cancer Communications. 2025;45(11):1513-1546. doi:10.1002/cac2.70067
BibTeX
@article{Yan2025,
author = {Yan, Yuheng and Tan, Ximin and Song, Bin and Yi, Ming and Chu, Qian and Wu, Kongming},
title = {Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy},
journal = {Cancer Communications},
year = {2025},
volume = {45},
number = {11},
pages = {1513--1546},
doi = {10.1002/cac2.70067}
}
EUVIMED